SQYG alleviated cognitive impairment of AD by regulating lipid metabolism, metal ion metabolism, IL-17 signaling pathway, GABA receptor signaling, and neuroactive ligand-receptor interaction. The gene discussed is IL17A; the disease is Alzheimer disease.